The hypoparathyroidism market is influenced by regional factors such as healthcare infrastructure, diagnosis rates, treatment access, and regulatory policies. While the market is global, there are notable differences in the prevalence and management of the disease across various regions. Understanding these regional dynamics is crucial for stakeholders looking to capitalize on the opportunities in the hypoparathyroidism market.
The hypoparathyroidism market is estimated to be valued at USD 731.1 Mn in 2024 and is expected to reach USD 1213.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
North America: The Largest Market
North America, particularly the United States, represents the largest market for Hypoparathyroidism Market. The region benefits from advanced healthcare infrastructure, high levels of awareness, and access to cutting-edge therapies. The U.S. Food and Drug Administration's (FDA) approval of recombinant PTH therapy has significantly impacted the market, with patients increasingly seeking out this advanced treatment option. Furthermore, the high incidence of thyroid surgeries and the associated risk of hypoparathyroidism have contributed to the growing patient population in North America.
Competitive overview of Hypoparathyroidism Market
The major players operating in the hypoparathyroidism market include Takeda Pharmaceutical Company Limited, Ascendis Pharma A/S, Amgen Inc., Entera Bio Ltd., Shire Plc, Roche Holding AG, Eli Lilly and Company, Forte Biosciences Inc., AbbVie Inc., and Novartis International AG.
In addition to recombinant PTH therapy, the widespread use of calcium and vitamin D supplements further drives market growth in the U.S. The availability of diverse treatment options and supportive healthcare policies make North America a key region for hypoparathyroidism drug manufacturers.
➣ Get More Insights On- Hypoparathyroidism Market
➣ Get this Report in Japanese Language: 甲状腺機能低下症市場
➣ Get this Report in Korean Language: 갑상선 기능 저하증 시장
